Non-myeloablative stem cell transplant (NMSCT) in AML, ALL, and MDS: Disappointing outcome for patients with advanced phase disease.

被引：0
|
作者：
Rezvani, K
Lalancette, M
Szydlo, R
Mackinnon, S
Blaise, D
Slavin, S
Alessandrino, EP
Michallet, M
Niederwieser, N
Apperley, J
Frassoni, F
机构：
[1] Hammersmith Hosp, London, England
[2] UCL, London, England
[3] Inst J Paoli I Calmettes, F-13009 Marseille, France
[4] Hadassah Univ, Jerusalem, Israel
[5] Policlin San Matteo, I-27100 Pavia, Italy
[6] Hop Edouard Herriot, Lyon, France
[7] Univ Leipzig, D-7010 Leipzig, Germany
[8] Osped San Martino Genova, Genoa, Italy
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2061
引用
收藏
页码：479A / 479A
页数：1
相关论文
共 50 条
  • [41] Non-myeloablative allogeneic stem cell transplant in a patient with refractory systemic lupus erythematosus
    Q Lu
    L Lu
    X Niu
    Y Guo
    G R Parino
    D Liu
    Bone Marrow Transplantation, 2006, 37 : 979 - 981
  • [42] SUCCESSFUL OUTCOME AFTER NON-MYELOABLATIVE ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH RENAL DYSFUNCTION
    Kersting, S.
    Verdonck, L.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 141 - 141
  • [43] Resolution of Behcet's disease after non-myeloablative allogeneic stem cell transplant for acute myeloid leukaemia
    Lim, S. H.
    Hulsey, M.
    Esler, W. V.
    RHEUMATOLOGY, 2009, 48 (01) : 88 - 89
  • [44] T cell depleted (TCD) allogeneic hematopoietic stem cell transplant for older patients with advanced MDS and AML evolved from MDS
    Tamari, R.
    Chung, S.
    Devlin, S.
    Jakubowski, A.
    Papadopoulos, E.
    Perales, M. A.
    Ponce, D.
    Goldberg, J.
    Barker, J.
    Sauter, C.
    Koehne, G.
    Young, J.
    Giralt, S.
    Castro-Malaspina, H.
    LEUKEMIA RESEARCH, 2013, 37 : S122 - S122
  • [45] Haploidentical, non-myeloablative stem-cell transplantation for advanced renal-cell carcinoma
    Satoh, M
    Miyamura, K
    Yamada, M
    Ishidoya, S
    Childs, RW
    Arai, Y
    LANCET ONCOLOGY, 2004, 5 (02): : 125 - 126
  • [46] Non-myeloablative stem cell transplantation for advanced renal cell carcinoma not responding to conventional immunotherapy
    Yun, T
    Lee, KW
    Na, IL
    Song, EK
    Shin, HC
    Lee, JH
    Choi, SJ
    Lee, JH
    Lee, KH
    Yoon, SS
    Lee, JS
    Park, S
    Kim, BK
    BONE MARROW TRANSPLANTATION, 2005, 35 : S257 - S257
  • [47] Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation
    Madlen Jentzsch
    Juliane Grimm
    Marius Bill
    Dominic Brauer
    Donata Backhaus
    Julia Schulz
    Karoline Goldmann
    Dietger Niederwieser
    Uwe Platzbecker
    Sebastian Schwind
    Blood Cancer Journal, 11
  • [48] A Retrospective Comparison of Outcomes in AML/MDS Patients Undergoing Allogeneic Stem Cell Transplant with Reduced Intensity and Myeloablative Conditioning Regimens
    Albabtain, Abdulwahab
    Kim, Seongho
    Uberti, Joseph
    Ratanatharathorn, Voravit
    Deol, Abhinav
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S258 - S259
  • [49] Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: Myeloablative, non-myeloablative, and beyond
    Hwang, Y. Y.
    Mohty, M.
    Chim, C. S.
    HEMATOLOGY, 2015, 20 (02) : 61 - 71
  • [50] Similar Outcomes Using Myeloablative Versus Reduced intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research
    Luger, Selina
    Ringden, Olle
    Perez, Waleska S.
    Zhang, Mei-Jie
    DiPersio, John F.
    Sierra, Jorge
    Tallman, Martin
    Weisdorf, Daniel J.
    Pulsipher, Michael
    BLOOD, 2008, 112 (11) : 136 - 136
12345